QOL Medical

What QOL Medical does

QOL Medical, LLC is a privately held specialty biopharmaceutical company founded in 2003 and headquartered in Vero Beach, Florida. The company focuses exclusively on the commercialization of FDA-approved pharmaceutical products for rare and orphan diseases that are underserved by larger biopharma firms, marketing three approved products: Sucraid (sacrosidase) Oral Solution for sucrase deficiency, Ethamolin (ethanolamine oleate) Injection 5% for bleeding esophageal varices, and Gimoti (metoclopramide) nasal spray for diabetic gastroparesis in adults (the last acquired via the December 2025 Evoke Pharma acquisition and carrying a boxed warning for tardive dyskinesia). QOL Medical operates in-house manufacturing for Sucraid, including chemistry labs, therapeutic production areas, and temperature-controlled storage, and distributes all three products via prescription through specialty pharmacy channels with dedicated product websites and a centralized customer service line.

The company's revenue model is direct prescription product sales of these three specialty therapeutics to rare disease patients and prescribers in the United States, with no international footprint. Go-to-market is sales-led, leveraging dedicated product websites, direct HCP/patient phone support, and CMS Open Payments transparency compliance under the U.S. Physician Payment Sunshine Act. Strategic posture is programmatic: the corporate 'Partnering' page explicitly identifies an appetite to acquire or partner on additional biopharmaceutical products for rare diseases, and the December 2025 Evoke Pharma acquisition (~$12.8M for 67.63% tendered at $11.00/share) is the first material execution of that roll-up strategy. The company employs 51-100 people, is structured as a Florida LLC with no public listing, and resolved a $47M DOJ False Claims Act settlement in fiscal year 2025, which materially constrained its financial flexibility alongside the recent acquisition.

Name

QOL Medical

Legal name

QOL Medical, LLC

Website

https://qolmed.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

QOL Medical, LLC is a privately held, Vero Beach-based specialty biopharmaceutical company founded in 2003 that commercializes three FDA-approved products (Sucraid, Ethamolin, Gimoti) for rare and orphan diseases in the US, distributing via specialty pharmacy and prescription channels.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals for Rare and Orphan Diseases

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Specialty biopharmaceuticals
• Orphan disease treatments
• Rare disease therapies
• Specialty prescription drugs
• FDA-approved pharmaceuticals

Headquarters

HQ city

Vero Beach

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Product Sales: QOL Medical generates revenue through the commercialization of FDA-approved specialty pharmaceutical products for rare and orphan diseases. The company markets three approved products: Sucraid (sacrosidase) Oral Solution, Ethamolin (ethanolamine oleate) Injection 5%, and Gimoti (metoclopramide) nasal spray. Revenue is derived from product sales to patients and healthcare providers in the rare disease market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

QOL Medical is a specialty biopharmaceutical company that markets three FDA-approved products for rare and orphan diseases: Sucraid (sacrosidase) Oral Solution for sucrase deficiency, Ethamolin (ethanolamine oleate) Injection 5% for bleeding esophageal varices, and Gimoti (metoclopramide) nasal spray for diabetic gastroparesis. The company focuses on commercializing orphan products for underserved markets, providing expanded clinical awareness and patient access. Following the December 2025 acquisition of Evoke Pharma, the portfolio was expanded and Gimoti retained as a wholly owned product line. The company manufactures Sucraid in-house and sells all products via prescription through U.S. specialty distribution channels.

Product overview

QOL Medical is a specialty biopharmaceutical company that markets three FDA-approved products: Sucraid (sacrosidase) Oral Solution, Ethamolin (ethanolamine oleate) Injection 5%, and Gimoti (metoclopramide) nasal spray. These products address rare and orphan diseases, including sucrase deficiency, esophageal varices bleeding, and diabetic gastroparesis. The company focuses on commercialization of orphan products for underserved markets, providing expanded clinical awareness and patient access for rare disease treatments.

Differentiator

Problem solved

Functional benefit

Brands

• Sucraid: Sucraid (sacrosidase) Oral Solution - FDA-approved orphan drug for rare disease treatment
• Ethamolin
• Gimoti

Products and services

• Sucraid (sacrosidase) Oral Solution Sacrosidase oral solution FDA-approved for the treatment of sucrase deficiency, a rare genetic disorder affecting the digestion of sugars; manufactured in-house at the QOL Medical facility and targeted to patients with congenital sucrase-isomaltase deficiency.
• Ethamolin (ethanolamine oleate) Injection 5% Ethanolamine oleate injection 5% FDA-approved for the treatment of bleeding esophageal varices, used in interventional gastroenterology and hepatology procedures for patients with this vascular complication.
• Gimoti (metoclopramide) nasal spray Metoclopramide nasal spray FDA-approved for the treatment of symptoms associated with acute and recurrent diabetic gastroparesis in adults; carries a boxed warning for tardive dyskinesia and is contraindicated in patients with a history of the condition.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Evoke PharmamajorOthers · 4 November 2025QOL Medical acquired Evoke Pharma through a tender offer at $11.00 per share in cash (a 139.7% premium to Evoke's recent Nasdaq closing price), followed by a merger. The transaction was approved by both boards and closed on December 15-17, 2025. Approximately 1,164,862 shares (67.63% of Evoke's outstanding shares) were validly tendered. Following the merger, Evoke became a wholly owned subsidiary of QOL Medical, and Evoke's common stock ceased trading on Nasdaq. QOL Medical expanded its portfolio through this acquisition.

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• Anika Therapeutics: Small-cap U.S. specialty biopharmaceutical company marketing a focused portfolio of FDA-approved therapeutics. Comparable to QOL in scale, single-geography commercial footprint, and dependence on a small number of promoted products.
• Eagle Pharmaceuticals: U.S. specialty pharma commercializing a small set of differentiated, branded pharmaceutical products. Comparable to QOL in go-to-market approach (sales-led, specialty distribution) and reliance on a limited product portfolio for revenue.
• Collegium Pharmaceutical: Specialty pharma with a focused portfolio of small branded prescription products commercialized to defined physician audiences. Similar in size, structure, and product-portfolio concentration to QOL.
• Pacira BioSciences: Specialty biopharmaceutical company commercializing a small set of branded pharmaceutical products in defined therapeutic areas. Comparable to QOL in commercial model and product-portfolio-driven revenue.
• Recordati Rare Diseases: Specialty pharma division explicitly focused on rare/orphan disease treatments. Direct functional peer to QOL's orphan-disease commercialization strategy and patient-access model.
• Cumberland Pharmaceuticals: Small U.S. specialty pharma with a portfolio of branded, hospital-and-specialty prescription products. Comparable to QOL in size, distribution model, and concentration in a handful of marketed drugs.
• Supernus Pharmaceuticals: Mid-sized specialty pharma with a compact portfolio of CNS and other branded products commercialized to specialty physicians. QOL shares the specialty-commercial, multi-product-but-narrow-portfolio profile.

Broad incumbents

• Salix Pharmaceuticals: Specialty pharma with a long history in gastroenterology products including treatments relevant to QOL's Ethamolin and Gimoti GI indications. Comparable in therapeutic area and specialty-prescriber channel, though broader in portfolio.
• Swedish Orphan Biovitrum (Sobi): Established rare-disease specialty pharma with a global portfolio of orphan products. Comparable in therapeutic focus (rare disease) and commercialization approach, though much larger in scale and geography than QOL.
• Jazz Pharmaceuticals: Larger specialty biopharma with a portfolio of rare-disease and neuroscience products. Broader and more diversified than QOL, but operates with the same specialty-pharma playbook QOL uses for Sucraid and Ethamolin.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QOL Medical